Business Context and Reporting Period
This Form 8-K was filed by SCYNEXIS, Inc. on August 11, 2015. The filing serves as a Regulation FD disclosure regarding investor meetings scheduled for the Canaccord Genuity 35th Annual Growth Conference on August 12–13, 2015, in Boston, Massachusetts. The report details the company's development strategy and outlook for its lead product candidate, SCY-078.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development updates and does not contain financial statements.
Material Changes and Development Updates
- Phase 2 Oral Study (Invasive Candida): Enrollment in the multicenter Phase 2 study for the oral formulation of SCY-078 has been slower than anticipated. The company has opened new sites, amended the protocol, and plans to open additional sites in the US and internationally to accelerate enrollment. Top-line data is expected in the first half of 2016.
- IV Formulation: Following a pre-submission meeting with the FDA, the company plans to submit data from IND-enabling studies and initiate the first Phase 1 study for the IV formulation in the fourth quarter of 2015.
- New Indication (VVC): The company plans to commence a Phase 2 study in the fourth quarter of 2015 to evaluate SCY-078 for vulvovaginal candidiasis (VVC), specifically targeting azole-resistant Candida spp. Top-line results are expected in the first half of 2016.
Guidance, Outlook, and Risks
Management's outlook centers on the successful execution of clinical trials for SCY-078 across multiple formulations and indications. Key risks identified include the slower-than-anticipated enrollment in the current Phase 2 study, which necessitates protocol amendments and site expansion. The company is also evaluating the actual number of patients required to achieve study objectives as data collection progresses.
Investor Verification Checklist
- Verify the progress of enrollment in the Phase 2 oral study for invasive Candida infections.
- Confirm the timeline for the submission of the IV formulation data package and the start of Phase 1 trials in Q4 2015.
- Monitor the initiation of the Phase 2 study for vulvovaginal candidiasis (VVC) in Q4 2015.
- Review the attached Corporate Presentation (Exhibit 99.1) for detailed strategic slides, noting that this presentation is not deemed "filed" under Section 18 of the Exchange Act.